Is Epitalon approved or legal?

No regulator (FDA, EMA, MHRA) has approved Epitalon for any human therapeutic use. In the US, EU, UK, and most jurisdictions it is sold for laboratory research use only and is not approved for human consumption. Legality of possession varies, but it is not a licensed medicine.

What dose and half-life does Epitalon have?

Its blood half-life is very short (estimated on the order of minutes), yet effects are hypothesized to persist via gene-level action. Anecdotal community protocols cite roughly 5 mg/day for 20 days or 10 mg/day for 10 days subcutaneously, 1-3 cycles per year - this is research-reference information, not medical advice, and there is no regulator-established human dose.

What is the strongest evidence for Epitalon?

The strongest mechanistic evidence is in-vitro telomerase activation and telomere elongation in human cell cultures (preclinical). Human longevity claims rest mainly on non-blinded cohort studies from a single Russian group and have not been independently replicated to clinical-trial standards.

Does Epitalon cause cancer or is it dangerous?

Reported tolerability is generally good, with injection-site reactions being most common. Because it can activate telomerase, there is a theoretical concern about promoting abnormal cell proliferation, though animal studies have reported reduced tumor incidence. Long-term human safety is not well established, and unregulated product purity is an additional real-world risk.

How is Epitalon administered?

It is most commonly used as a subcutaneous injection in short intensive cycles; intramuscular and intranasal routes are also described in the literature and community use. It is reconstituted from lyophilized powder before injection.

Longevity

Epitalon

Also known as: Epithalon, Epithalamin, AEDG, Ala-Glu-Asp-Gly

Synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) studied as a telomerase activator; human evidence is limited and mostly from one Russian group.

Last updated July 11, 2026

Reconstitute this peptide Buy Epitalon

Overview

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), identified as the putative active fragment of epithalamin, a bovine pineal gland extract. It is studied primarily as a longevity or "anti-aging" compound, with most research focused on telomere biology, circadian/melatonin regulation, and age-related decline. The great majority of human and animal data originate from the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson, over several decades. This concentration in a single research group, often with non-blinded designs, is the central limitation of the evidence base and the reason claims should be read cautiously. In the United States, EU, UK, and most Western jurisdictions, Epitalon is sold for laboratory research use only and is not approved by any regulator for human therapeutic use. The information below is a research reference and is not medical advice.

How it works

Epitalon's most-cited proposed mechanism is activation of telomerase: in telomerase-negative human fetal fibroblast cultures it induced expression of the telomerase catalytic subunit (hTERT) and measurable telomere elongation, allowing cells to surpass the Hayflick limit in vitro. It is also described as a peptide bioregulator thought to influence gene expression and to help normalize pineal function, including restoration of melatonin secretion and circadian rhythm in aged subjects. Because it is a very small peptide cleared from blood within minutes, researchers hypothesize that its durable effects reflect action on gene activity rather than sustained circulating levels. Much of the mechanistic detail remains preclinical and not independently confirmed at scale.

Researched effects

Preclinical Activates telomerase (hTERT) and elongates telomeres in human somatic cell cultures, extending replicative lifespan past the Hayflick limit
Anecdotal Reported increased telomere length in blood cells of elderly subjects (60-80) in non-blinded single-group studies
Anecdotal Associated with reduced mortality (reported ~1.6-1.8 fold) in one long-term non-blinded elderly cohort; not independently replicated
Anecdotal Reported restoration of melatonin secretion and normalized circadian/sleep patterns in aged subjects (low-rigor human data)
Preclinical Reduced spontaneous tumor incidence and chromosomal aberrations, and extended lifespan in rodents
Preclinical Improved antioxidant enzyme activity and reduced oxidative markers in animal models
Anecdotal Self-reported improvements in sleep quality, recovery, and general wellbeing

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No regulator-established human therapeutic dosing exists. In the Russian clinical literature (Khavinson group), Epitalon/Epithalamin was typically administered parenterally in short intensive courses, often around 5-10 mg per day for 10-20 consecutive days, repeated periodically (e.g., one to several courses per year over multiple years). These protocols come from non-blinded studies by a single group and should not be treated as validated clinical guidance.

Community-reported dosing (anecdotal)

ANECDOTAL / RESEARCH-REFERENCE ONLY - not medical advice or instruction. Community and vendor guides (peptide forums, dosing-calculator sites, and r/Peptides-style discussion) commonly describe subcutaneous protocols such as ~5 mg/day for 20 days, or ~10 mg/day for 10 days (roughly a 100 mg total per cycle), typically run as 1-3 short cycles per year with several months off between cycles. Reported reconstitution is with bacteriostatic water, with nightly dosing being a common preference. Users generally report no ramp-up and advise skipping (not double-dosing) a missed day. These figures are unverified community conventions, vary widely by source, and carry no safety guarantees.

Half-life: Very short (estimated on the order of minutes); rapidly cleared from circulation, with biological effects hypothesized to persist beyond measurable blood levels
Routes: subcutaneous, intramuscular, nasal

Safety & side effects

Human safety data are limited and come largely from one research group, so the long-term profile is not well characterized by independent, blinded studies. Reported tolerability in the available literature and community use is generally good, with the most common complaints being injection-site reactions (redness, irritation, bruising). A theoretical concern with any telomerase-activating compound is that increased telomerase activity could, in principle, favor proliferation of abnormal or pre-cancerous cells; this risk has not been adequately studied in humans for Epitalon, though animal studies have reported reduced tumor incidence. Product purity and sterility are real-world concerns since material is sold as research-use-only and is unregulated. Anyone considering use should treat it as experimental and consult a qualified clinician; it is not approved for human consumption.

Research summary

The signature finding for Epitalon is in vitro telomerase activation: a 2003 study in Bulletin of Experimental Biology and Medicine showed that adding the peptide to telomerase-negative human fibroblasts induced hTERT expression and telomere elongation, letting cells divide beyond their normal limit. This is robust as a cell-culture result but is preclinical and does not by itself establish clinical benefit. Supporting animal work from the same lineage of researchers reports reduced spontaneous tumors, lower chromosomal damage, improved antioxidant status, and modest lifespan extension across several species. Human evidence is thinner and methodologically weaker. The most-cited longevity claim comes from a long-term cohort of 266 elderly persons (Khavinson and Morozov, Neuroendocrinology Letters, 2003) reporting mortality reductions of roughly 1.6-1.8 fold for Epithalamin alone and up to ~4.1 fold for repeated combined courses with thymalin. These were non-blinded, single-group studies without the design rigor of modern randomized controlled trials, and independent Western replication is essentially absent. Reports of increased telomere length in older patients and restored melatonin secretion are intriguing but share the same limitations. Taken together, Epitalon has a genuinely interesting and reproducible in-vitro mechanism, suggestive preclinical longevity data, and a small body of low-rigor human data dominated by one institution. It remains research-use-only and unapproved. Claims of "anti-aging" or life extension in humans are not established to a clinical standard, and prospective, blinded, independent trials would be needed before any therapeutic conclusions could be drawn.

FAQ

Is Epitalon approved or legal?: No regulator (FDA, EMA, MHRA) has approved Epitalon for any human therapeutic use. In the US, EU, UK, and most jurisdictions it is sold for laboratory research use only and is not approved for human consumption. Legality of possession varies, but it is not a licensed medicine.
What dose and half-life does Epitalon have?: Its blood half-life is very short (estimated on the order of minutes), yet effects are hypothesized to persist via gene-level action. Anecdotal community protocols cite roughly 5 mg/day for 20 days or 10 mg/day for 10 days subcutaneously, 1-3 cycles per year - this is research-reference information, not medical advice, and there is no regulator-established human dose.
What is the strongest evidence for Epitalon?: The strongest mechanistic evidence is in-vitro telomerase activation and telomere elongation in human cell cultures (preclinical). Human longevity claims rest mainly on non-blinded cohort studies from a single Russian group and have not been independently replicated to clinical-trial standards.
Does Epitalon cause cancer or is it dangerous?: Reported tolerability is generally good, with injection-site reactions being most common. Because it can activate telomerase, there is a theoretical concern about promoting abnormal cell proliferation, though animal studies have reported reduced tumor incidence. Long-term human safety is not well established, and unregulated product purity is an additional real-world risk.
How is Epitalon administered?: It is most commonly used as a subcutaneous injection in short intensive cycles; intramuscular and intranasal routes are also described in the literature and community use. It is reconstituted from lyophilized powder before injection.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.